Management

TetiereCompany
FlecheManagement

MUTABILIS, a pharmaceutical R&D company, subsidiary of PharmaOmnium (POI).

Stéphane HUGUET

Stéphane HUGUET

President

Stéphane Huguet is an emergency care physician by training and holds an MBA from the INSEAD. He has held several management positions in pharmaceutical companies in Europe, the United States and Canada. In 2000, he created and developed two startup, one in the field of biotechnology, which was sold to a major US pharmaceutical company. The other, which marketed pharmaceutical products in France, was sold to POI. Stéphane Huguet now runs POI and its subsidiaries.

Sophie CHASSET

Sophie CHASSET

Director of Medicinal Chemistry

After a PhD in Chemistry and Physico-chemistry of compounds with biological value in 1996, Sophie CHASSET began her industrial career in 1997 as a medicinal chemist in the field of the Central Nervous System at the Laboratoire Louis Lafon (bought by Cephalon). In 2007, Sophie joined Novexel as group leader in anti-infectious medicinal chemistry and project leader on antibacterial Discovery. Following Novexel’s acquisition by Astra Zeneca in 2010 Sophie CHASSET joined Mutabilis as Director of Antiviral Chemistry. Since 2015 she is heading Mutabilis’ Medicinal Chemistry with a team of 14 chemists. Sophie CHASSET co-authored 6 publications and 14 patents or patent applications.

François MOREAU

François MOREAU

Biology Vice President & Scientic Director

François Moreau has over 20 years’ experience in the pharmaceutical industry. After a PhD in bio-organic chemistry in Paris, he joined Pfizer in 1998 as a group leader in enzymology/HTS in the therapeutic area of allergy and respiratory diseases. He joined MUTABILIS in 2004 and contributed to the development of new classes of antibacterials such as FabI inhibitors. François Moreau is the co-author of 24 articles and co-inventor of 11 patents, primarily in the field of the inhibition of bacterial virulence. At MUTABILIS he leads the multidisciplinary team of biochemists, microbiologists, virologists and pharmacologists. He also supervises external studies in ADME and the toxicology of drug candidates.